Top Markets
#1 ADO Protocol ADO Protocol +334.62%
#2 Islamic Coin Islamic Coin +155.44%
#3 Starpower Starpower +38.59%
#4 GoPlus Security GoPlus Security +36.89%
#5 GAIB AID GAIB AID +24.67%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.71%
#7 The Black Bull The Black Bull +11.74%
#8 Nockchain Nockchain +11.72%
#9 o1.exchange o1.exchange +11.53%
#10 Casper Network Casper Network +11.03%
Coin of the day
ADO Protocol ADO Protocol
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

CUPR
Rang in Aktien #33380
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical... Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Aktienkurs
$2.90
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$7.78M
Veränderung (1 Tag)
-6.45%
Veränderung (1 Jahr)
-69.54%
Land
SG
Handel Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

Kategorie

Healthcare
P/B-Verhältnis für Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Cuprina Holdings (Cayman) Limited Class A Ordinary Shares beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für Cuprina Holdings (Cayman) Limited Class A Ordinary Shares von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE